Table 1. Clinico-pathological characteristics of METABRIC cohort based on WRN and Top1 expression.
| Variable | WRN mRNA Expression | P Values | Topo I mRNA Expression | P Values | ||
|---|---|---|---|---|---|---|
| Low | High | Low | High | |||
| n (%) | n (%) | n (%) | n (%) | |||
| Lymph node stage | ||||||
| Negative | 139 (42.8) | 896 (54.4) | 0.001 | 835 (52.8) | 200 (51.3) | 0.389 |
| Positive (1-3) | 65 (20.0) | 249 (15.1) | 243 (15.4) | 71 (18.2) | ||
| Positive (> 3) | 121 (37.2) | 501 (30.4) | 503 (31.8) | 119 (30.5) | ||
| Grade | ||||||
| G1 | 17 (5.4) | 152 (9.6) | 0.002 | 155 (10.2) | 14 (3.8) | 2.2×10−10 |
| G2 | 113 (36.1) | 657 (41.7) | 656 (43.1) | 114 (31.0) | ||
| G3 | 183 (58.5) | 767 (48.7) | 710 (26.5) | 240 (64.9) | ||
| Tumour Size (cm) | ||||||
| T 1a+b (1.0) | 14 (4.3) | 78 (4.8) | 0.073 | 79 (5.0) | 13 (3.3) | 0.021 |
| T 1c (> 1.0-2.0) | 106 (32.9) | 660 (40.8) | 634 (40.4) | 132 (33.9) | ||
| T2 (> 2.0-5) | 183 (56.8) | 818 (50.0) | 782 (49.9) | 219 (56.3) | ||
| T3 (> 5) | 19 (5.9) | 79 (4.8) | 73 (4.7) | 25 (6.4) | ||
| NPI | ||||||
| ≤ 3.4 | 46 (14.8) | 342 (21.9) | 0.005 | 345 (22.9) | 47 (12.8) | 2.0×10−5 |
| > 3.4 | 265 (85.2) | 1217 (78.1) | 1162 (77.1) | 320 (87.2) | ||
| Her2 over expression | ||||||
| No | 264 (81.0) | 1468 (88.9) | 7.1×10−5 | 1424 (89.8) | 308 (78.8) | 3.2×10−9 |
| Yes | 62 (19.0) | 183 (11.1) | 162 (10.2) | 83 (21.2) | ||
| ER | ||||||
| Negative | 60 (18.4) | 410 (24.8) | 0.013 | 354 (22.3) | 116 (29.7) | 0.002 |
| Positive | 266 (81.6) | 1241 (75.2) | 1232 (77.7) | 275 (70.3) | ||
| PgR | ||||||
| Negative | 155 (47.5) | 781 (47.3) | 0.936 | 716 (45.1) | 220 (56.3) | 8.0×10−5 |
| Positive | 171 (52.5) | 870 (52.7) | 870 (54.9) | 171 (43.7) | ||
| Genefu subtype | ||||||
| ER-/Her2 - | 9 (5.5) | 141 (17.0) | 1.7×10−4 | 124 (15.5) | 26 (13.1) | 0.538 |
| ER+/Her2-/high proliferation | 81 (49.4) | 285 (34.3) | 2.6×10−4 | 279 (76.2) | 87 (23.8) | 0.053 |
| ER+/Her2-/low proliferation | 45 (27.4) | 323 (38.9) | 0.005 | 326 (40.9) | 42 (21.2) | 1.0×10−5 |
| Her-2 positive | 29 (17.7) | 81 (9.8) | 0.003 | 67 (8.4) | 43 (21.7) | 4.9×10−7 |
| PAM50 subtype | ||||||
| PAM50.Her2 | 52 (17.9) | 186 (12.6) | 0.014 | 159 (11.3) | 79 (21.4) | 4.4×10−7 |
| PAM50.Basal | 28 (9.7) | 302 (20.4) | 1.8×10−5 | 266 (19.0) | 64 (17.4) | 0.478 |
| PAM50.LumA | 98 (33.8) | 617 (41.6) | 0.013 | 613 (43.7) | 102 (27.6) | 2.0×10−6 |
| PAM50.LumB | 112 (38.6) | 377 (25.4) | 4.0×10−6 | 365 (26.0) | 124 (33.6) | 0.004 |
| IntClust subgroups | ||||||
| intClust.1 | 35 (10.7) | 102 (6.2) | 0.003 | 95 (6.0) | 42 (10.7) | 0.001 |
| intClust.2 | 17 (5.2) | 55 (3.3) | 0.097 | 54 (3.4) | 18 (4.6) | 0.257 |
| intClust.3 | 28 (8.6) | 262 (15.9) | 0.001 | 251 (15.8) | 39 (10.0) | 0.003 |
| intClust.4 | 32 (9.8) | 311 (18.8) | 8.5×10−5 | 308 (19.4) | 35 (9.0) | 9.7×10−7 |
| intClust.5 | 53 (16.3) | 136 (8.2) | 7.0×10−6 | 118 (7.4) | 71 (18.2) | 1.1×10−10 |
| intClust.6 | 29 (8.9) | 57 (3.5) | 1.1×10−5 | 66 (4.2) | 20 (5.1) | 0.408 |
| intClust.7 | 42 (12.9) | 147 (8.9) | 0.026 | 157 (9.9) | 32 (8.2) | 0.302 |
| intClust.8 | 30 (9.2) | 270 (16.4) | 0.001 | 251 (15.8) | 49 (12.5) | 0.104 |
| intClust.9 | 48 (14.7) | 98 (5.9) | 2.9×10−8 | 117 (7.4) | 29 (19.9) | 0.978 |
| intClust.10 | 12 (3.7) | 213 (12.9) | 2.0×10−6 | 169 (10.7) | 56 (14.3) | 0.041 |
HER2: human epidermal growth factor receptor 2; ER: estrogen receptor; PgR: progesterone receptor; Triple negative: ER−/PgR−/HER2−.